←Back to Expert Scholars
Translational Medicine / 转化医学NTRK and Rare Gene Fusions
David Hyman
MD
🏢Related Sciences🌐USA
Chief Medical Officer
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
David Hyman pioneered basket trial methodology for NTRK fusion-positive cancers at MSKCC that led to the approval of larotrectinib. His innovative trial designs demonstrated that molecular alterations rather than tumor histology can drive treatment decisions. He has been a transformative figure in precision oncology trial design.
Share:
🧪Research Fields 研究领域
NTRK fusions
Basket trials
Tumor-agnostic therapy
HER2 mutations
Precision oncology
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 David Hyman 的研究动态
Follow David Hyman's research updates
留下邮箱，当我们发布与 David Hyman（Related Sciences）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment